CLINICAL RESEARCH CENTER - ADMN CORE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 临床研究中心为IRB批准的临床研究提供行政、护理和辅助支持。该中心本身不进行人体研究。该中心还支持对公共领域开放的二级数据库的研究。 描述(改编自申请者S摘要)：通过RCMI临床研究基础设施倡议为RCMI-CRC请求持续支持。具体地说，要求继续提供支助，用于增加护理和膳食工作人员、接受过临床培训的流行病学家/生物统计学家以及扩大卫生保健中心。在德鲁的RCMI-CRC最初的资助申请是扩大该机构以患者护理为导向的研究机会的第一个关键步骤。从历史上看，RCMI-CRCs在医学进步中发挥了重要作用，从而为医疗实践和卫生保健质量设定了标准。RCMI-CRC在DREW的存在导致了致力于调查对少数群体和弱势群体影响不成比例的健康问题的临床研究人员和项目的数量增加。此外，RCMI-CRC的出现增加了Drew与UCLA医学院、Harbor/UCLA、USC、MCW、纽约州西奈山医学中心、JHU和Duke之间的合作临床研究活动。在RCMI支持的最初四年中，DREW以患者护理为导向的研究活动从8个增加到12个；公共卫生服务(PHS)；即国家卫生研究院(NIH)、疾病控制中心(CDC)资助的临床研究研究(增加50%)。最近又资助了另外五个项目，以及正在审查的另外三个小灵通申请。这些项目对德鲁来说是一个非同寻常的机会。不幸的是，在没有额外支持的情况下，RCMI-CRC无法处理增加的需求。为了应对这一机构增长，必须增加资金，以扩大RCRII-CRC的能力。因此，这次续签申请的广泛目标是扩大临床研究活动的广度，并维持越来越多的活跃的临床研究人员。 荷尔蒙分析核心实验室是在RCMI临床研究中心基础设施倡议的支持下于1996年成立的，目的是通过开发和提供当时研究人员无法获得的荷尔蒙测量方法，扩大查尔斯·R·德鲁医科大学的荷尔蒙分析能力。自三年前成立以来，荷尔蒙分析实验室不仅实现了最初的所有目标，而且在新的测试开发和分析改进方面已经超过了它们在下一个资助期核心实验室将实现以下目标：1)继续为德鲁大学提供激素分析能力，不仅执行一些专门的分析，而且通过提供设施有序存储和分发临床研究的血液样本2)现有的分析和开发新的激素和分析测试方法将通过适应和开发高通量测试的新技术来改进，以便快速转变为更常用的激素测试。已开发出新的分析方法：a)用高灵敏的平衡透析法测定女性体内的游离睾酮；b)用肌肉生长抑素放射免疫法测定。在下一个资金阶段，我们计划向我们的用户提供以下检测：a)胰岛素，b)C-肽，c)IGF-1，d)IGFBP-3，和e)C反应蛋白。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Clinical Research Center provides administrative, nursing, and ancillary support for IRB approved clinical studies. The Center itself does not perform human research. The Center also supports research on secondary databases open to the public domain. DESCRIPTION (Adapted from the applicant''s abstract): Continued support is requested through the RCMI Clinical Research Infrastructure initiative for the RCMI-CRC. Specifically, continued support isrequested for the an increase in the nursing and dietary staffing, aclinically trained epidemiologist/biostatistician and expansion of the HAC. The original funded application for the RCMI-CRC at Drew was the first crucial step toward expanding patient care oriented research opportunities at the institution. Historically, RCMI-CRCs have played an influential role in medical advances, thereby setting standards for the practice of medicine and the quality of health care. The presence of a RCMI-CRC at Drew has led to an increase in the number of clinical research faculty and projects dedicated to the investigation of health issues that disproportionately affect minorities and disadvantaged populations. In addition, the presence of an RCMI-CRC has led to an increase in collaborative clinical research activities between Drewand the UCLA School of Medicine, Harbor/UCLA, USC, MCW, Mount Sinai Medical Center, N.Y., JHU, and Duke. During the initial four years of RCMI support, patient care oriented research activities have increased at Drew from eight to twelve; Public Health Service (PHS); i.e. National Institutes of Health (NIH), Centers for Disease Control(CDC)-funded clinical research studies (50 percent increase). An additional five projects have recently been funded as well as another three PHS applications under review. These projects represent an extraordinary opportunity for Drew. Unfortunately, without additional support, the RCMI-CRC is unable to handle the increased demand. In response to this institutional growth, increased funding is essentia lto expand RCRII- CRC capacity. As such, the broad objective of this renewal application is to expand the breadth of clinical research activities and sustain an increasing number of active clinical research faculty. The Hormone Assay Core Lab was established in 1996 under the auspices of the RCMI Clinical Research Center Infrastructure Initiative to expand the hormone assay capabilities at the Charles R. Drew University of Medicine and Science, by developing and making available hormone measurement methods that were not available to the investigators at that time. Since its inception 3 years ago, the Hormone Assay Laboratory has not only achieved all of its original goals, but has surpassed them in the area of new assay development and assay refinement In the next grant period the Core Laboratory will achieve the following objectives: 1) Continue to provide hormone assay capability at Drew University by not only performing some specialized assays, but by also providing facilities for orderly storage and distribution of blood samples from clinical research studies 2)Existing assays and develop new assays for the measurements of hormones and analytes will be improved by adapting and developing novel technologies for high throughput assays for rapid turnaround formore commonly used hormone measurements. New assays have been developed a) Measurement of Free Testoterone in Women by using a Highly Sensitive Equilibrium Dialysis Assay, b) Myostatin Radioimmunoassay. In the next funding period, we plan to provide the following assays to our users: a) Insulin, b) C-peptide, c)IGF-1,d)IGFBP-3, and e) C reactive protein.